HOME >> BIOLOGY >> NEWS
Inhibition of cathepsin proteases inhibits tumor formation in transgenic mice

A new research study provides evidence that inhibition of cathepsin cysteine proteases may be a viable strategy for treatment of human cancers. Cathepsins are shown to be involved in multiple stages of tumor development in transgenic mouse models of cancer, and pharmacological inhibition of cathepsins impairs tumor growth and progression. The research is published in the May issue of Cancer Cell.

Molecules known as proteases have long been linked with cancer in humans, and the cathepsins are known to be associated with some human malignancies. However, a specific role for cysteine cathepsin proteases in tumor progression has not been examined in detail, and cathepsins as a potential therapeutic target for treatment of cancer have not been previously reported. Dr. Matthew Bogyo from Stanford Medical School and Dr. Douglas Hanahan from the University of California at San Francisco and colleagues demonstrated that cathepsins are elevated in tumors that form in a mouse model of a rare form of pancreatic cancer and a mouse model of cervical cancer. Using specialized chemical reporters that detected enzymatic activity of cathepsins, the researchers revealed that elevated cathepsins activity in tumors was correlated with the formation of tumor blood vessels (angiogenesis), tumor growth, and invasion into normal tissue in these tumor-bearing mice.

Furthermore, treatment of the cancer-prone mice with a pharmacological inhibitor of cysteine cathepsin activity disrupted both early and late stages of tumor development. The effective dose of the inhibitor was not toxic to normal cells, suggesting that it may be a potential candidate for use in the treatment of human cancers.

These results point to cathepsins as a viable target for future anticancer therapeutics. According to Dr. Hanahan, "It is reasonable to suggest that cathepsin inhibitors may show combinatorial benefits with other targeted (and traditional) therapies, which could be revealed in precli
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
17-May-2004


Page: 1 2

Related biology news :

1. Inhibition of insulin-like growth factor receptor-1 as promising anticancer therapeutic
2. Inhibition of Borrelia burgdorferi protein may reduce Lyme disease transmission
3. Inhibition Of A Novel Gene Involved In Phosphorylating Starch In TransgenicPotato Tubers Leads To The Repression Of Cold Induced Sweetening
4. Competitive Inhibition May Enhance Safety Of Minimally Processed Fruits And Vegetables
5. Marijuana ingredient inhibits VEGF pathway required for brain tumor blood vessels
6. The amendment to the law on green Genetic Engineering inhibits innovation and research in Germany
7. Obesity drug inhibits prostate tumor growth
8. Protein inhibits cell growth, may contribute to breast cancer
9. ENBREL combo therapy inhibits joint damage progression, offers significant RA symptom relief
10. Aspirin inhibits ovarian cancer growth, lab study finds
11. UIC chemists identify compound that inhibits cell migration

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 25, 2020 , ... Modality Solutions, a biopharmaceutical ... annual Inc. 5000 list. The list is the most prestigious ranking of the nation’s ... and for this year’s list, reported three-year revenue growth of 71 percent. , ...
(Date:8/21/2020)... ... August 19, 2020 , ... ... and expo uniting life science, data science, informatics and IT leaders goes VIRTUAL ... this period of uncertainty and change, Bio-IT takes the leadership role of keeping ...
(Date:8/7/2020)... ... August 06, 2020 , ... Alucio™, a fast-growing provider ... Eric Chen and Jessica Wong have joined the company’s leadership team as Vice ... Eric Chen heads development efforts for Alucio’s flagship product, Beacon, an innovative cloud-based ...
Breaking Biology News(10 mins):
(Date:8/15/2020)... ... August 13, 2020 , ... True Terpenes , the leading platform ... Advisory Board (SAB) to research the medical potential of terpenes and the potential ... with terpenes. The board is focused on expanding the recently launched line of effects-based ...
(Date:8/12/2020)... ... August 11, 2020 , ... The ... the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research Network (FSHD CTRN), with ... network is a consortium of academic research centers in the United States and ...
(Date:8/12/2020)... BINGHAM FARMS, Mich. (PRWEB) , ... August 12, ... ... International Consulting Group, Inc. (EMMA International), a global leader in FDA compliance ... ranking of the nation’s fastest-growing private companies. The list represents a unique look ...
(Date:8/3/2020)... PHILADELPHIA (PRWEB) , ... August 03, 2020 , ... ... data collection, today announced Jim Corrigan, President and CEO has been named one ... a broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on ...
Breaking Biology Technology:
Cached News: